Jaguar Animal Health, Inc. (NASDAQ:JAGX) Sees Significant Growth in Short Interest

Jaguar Animal Health, Inc. (NASDAQ:JAGX) saw a significant increase in short interest in the month of October. As of October 15th, there was short interest totaling 140,557 shares, an increase of 67.0% from the September 30th total of 84,156 shares. Based on an average trading volume of 4,969,953 shares, the days-to-cover ratio is presently 0.0 days. Approximately 40.7% of the company’s stock are sold short.

Jaguar Animal Health Stock Performance

JAGX opened at $1.62 on Monday. The firm has a fifty day moving average price of $6.46 and a 200 day moving average price of $123.15. The company has a debt-to-equity ratio of 0.35, a current ratio of 0.69 and a quick ratio of 0.40. Jaguar Animal Health has a 1 year low of $1.60 and a 1 year high of $1,102.50. The stock has a market cap of $3.16 million, a P/E ratio of -0.00 and a beta of -0.09.

Jaguar Animal Health (NASDAQ:JAGX) last announced its quarterly earnings results on Wednesday, August 19th. The biotechnology company reported ($15.70) earnings per share for the quarter, beating the consensus estimate of ($782.25) by $766.55. The business had revenue of $1.23 million during the quarter, compared to analysts’ expectations of $4.24 million.

Analyst Upgrades and Downgrades

JAGX has been the subject of a number of analyst reports. Wall Street Zen upgraded Jaguar Animal Health to a “sell” rating in a report on Saturday, October 10th. Weiss Ratings reissued a “sell (e+)” rating on shares of Jaguar Animal Health in a report on Thursday, October 15th. One investment analyst has rated the stock with a Sell rating. According to MarketBeat.com, the company presently has an average rating of “Sell”.

Jaguar Animal Health Company Profile

Jaguar Animal Health, Inc is a commercial-stage animal health company focused on developing and commercializing plant-based pharmaceuticals for gastrointestinal disorders in animals. Its research programs are designed to address conditions affecting companion animals, livestock and other animal species, with an emphasis on therapies that support intestinal function and overall animal health.

The company’s lead product is Canalevia-CA1, a prescription product containing crofelemer. Canalevia-CA1 received conditional approval from the U.S.